Figure S19 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

This is a Experimental Study study.

Key Points

Combination treatments were identified as effective for cancers with MTAP deletions and KRAS mutations.
MYC overexpression was validated in cell lines resistant to KRAS inhibitors, indicating a potential therapeutic target.
CRISPR-based screening was employed to identify and validate these combination therapies in engineered models.
This research highlights the importance of targeted combinations in overcoming drug resistance in cancer treatment.

Combinatorial screening identifies effective cancer treatments in engineered KRASi-resistant cell lines, suggesting new therapeutic strategies.

Figure S19. Validation of MYC overexpression and growth in the engineered KRASi-resistant cell lines.

No takes yet. Share an insight, caveat, or question.

Knoll et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share